Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi) Treatment-Naive Patients With Myelofibrosis: Updated Results and Subgroup Analyses from XPORT-MF-034

被引：0
|
作者：
Ali, Haris [1 ]
Kishtagari, Ashwin [2 ]
Maher, Keri [3 ]
Mohan, Sanjay [2 ]
Prchal, Josef [4 ]
Wang, Xulong [5 ]
Chamoun, Kamal [5 ]
Tantravahi, Srinivas [4 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] VCU Massey Canc Ctr, Richmond, CA USA
[4] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA
[5] Karyopharm Therapeut, Newton, MA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
myelofibrosis; selinexor; ruxolitinib; phase I;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-336
引用
收藏
页码：S389 / S389
页数：1
相关论文
共 27 条
  • [1] Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naive patients with myelofibrosis: Updated results from XPORT-MF-034
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Prchal, Josef T.
    Wang, Xulong
    Chamoun, Kamal
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naive Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification
    Tantravahi, Srinivas K.
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Prchal, Josef T.
    Wang, Xulong
    Chamoun, Kamal
    Walker, Christopher J.
    Taverna, Pietro
    Ali, Haris
    BLOOD, 2023, 142
  • [3] A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis (XPORT-MF-034)
    Maher, Keri
    Rampal, Raajit K.
    Bose, Prithviraj
    Podoltsev, Nikolai A.
    Harrison, Claire N.
    Hong, Junshik
    Wang, Xulong
    Chamoun, Kamal
    Mascarenhas, John
    BLOOD, 2023, 142
  • [4] Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).
    Mesa, Ruben A.
    Kiladjian, Jean -Jacques
    Catalano, John V.
    Devos, Timothy
    Egyed, Miklos
    Hellman, Andrzei
    McLornan, Donal
    Shimoda, Kazuya
    Winton, Elliott F.
    Deng, Wei
    Dubowy, Ronald L.
    Maltzman, Julia D.
    Cervantes, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
    Harrison, Claire N.
    Gupta, Vikas K.
    Gerds, Aaron T.
    Rampal, Raajit
    Verstovsek, Srdan
    Talpaz, Moshe
    Kiladjian, Jean-Jacques
    Mesa, Ruben
    Kuykendall, Andrew T.
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Grosicki, Sebastian
    Devos, Timothy
    Jourdan, Eric
    Wondergem, Marielle J.
    Al-Ali, Haifa Kathrin
    Buxhofer-Ausch, Veronika
    Alvarez-Larran, Alberto
    Patriarca, Andrea
    Kremyanskaya, Marina
    Mead, Adam J.
    Akhani, Sanjay
    Sheikine, Yuri
    Colak, Gozde
    Mascarenhas, John
    FUTURE ONCOLOGY, 2022, 18 (27) : 2987 - 2997
  • [6] A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naive Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)
    Scandura, Joseph M.
    Gerds, Aaron T.
    Ritchie, Ellen K.
    Wang, Xulong
    Kye, Steve
    Rampal, Raajit K.
    BLOOD, 2023, 142
  • [7] A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    CANCER RESEARCH, 2023, 83 (08)
  • [8] A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naive Myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay R.
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    BLOOD, 2022, 140 : 3986 - 3987
  • [9] A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Mazumder, Amitabha
    Chamoun, Kamal
    Karasik, Igor
    Sbar, Eric
    Dugon, Laura
    Tamir, Sharon
    Wang, Xulong
    Prchal, Josef T.
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naive Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24
    Mascarenhas, John
    Kremyanskaya, Marina
    Patriarca, Andrea
    Gupta, Vikas
    Palandri, Francesca
    Devos, Timothy
    Rampal, Raajit K.
    Talpaz, Moshe
    Vannucchi, Alessandro
    Kuykendall, Andrew
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    Mesa, Ruben
    Colak, Gozde
    Li, Qing
    Klein, Sandra
    Harrison, Claire
    BLOOD, 2022, 140
123